Navigation Links
Randomized Study Comparing Cell Therapeutics' OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Date:8/18/2011

leasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, Brown  and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from tim
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
3. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
10. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the enterprise ... and connectors for Lucene, SOLR and Elasticsearch. This ... for this high performance triplestore – GraphDB™ was ... interested in deploying the only mature enterprise resilient ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... -- A Geisinger researcher on a personal crusade against ... Disease Control and Prevention (CDC) award recognizing his unprecedented ... Joseph Boscarino , Ph.D. MPH, senior scientist, ... researchers nominated for the Centers for Disease Control and ... Methods and Study Design. "Hepatitis C killed ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... data on lead NNRTI, RDEA806, and next generation compounds to be ... ... Calif., Jan. 29 Ardea Biosciences,Inc. (Nasdaq: RDEA ) today ... family of compounds,including RDEA806, RDEA427 and RDEA640, will be presented during ...
... Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... of Neoplastic Cells from Mixed Cellular,Compositions using ... cancer cells ex vivo from blood stem ... modified vaccinia viruses, herpes simplex,viruses, parapoxviruses and ...
... CALGARY, Jan. 29 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, today ... The Instituto de Agrobiotecnologia,Rosario S.A. (INDEAR) based in ... by Bio Sidus AG S.A. and Bioceres S.A. ...
Cached Biology Technology:Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 2Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 3Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent 2SemBioSys signs option agreement for safflower-produced food ingredient 2SemBioSys signs option agreement for safflower-produced food ingredient 3
(Date:8/19/2014)... retail seafood counters in 10 different states show ... to unexpectedly high levels of mercury, a harmful ... fish of the same species, but from a ... according to new research by University of Hawai,i ... is essential to allow consumers to choose sustainable ...
(Date:8/19/2014)... ( Aug. 19, 2014 ) -- Scientists at the ... pick up and transfer single cells using a pipette ... They describe this engineering feat and preliminary test results ... the American Chemical Society . , "Studying single cells ... current biomedical research," said nanomedicine department. faculty member Lidong ...
(Date:8/19/2014)... glass of fizzy soda knows that bubbles can throw ... with wide industrial applications, Princeton researchers have demonstrated that ... liquid as well. , "It is well known that ... and fascinated, to discover that when we covered the ... droplets into the water," said Howard Stone, the Donald ...
Breaking Biology News(10 mins):Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3Moving single cells around -- accurately and cheaply 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3
... used a gene transfer technique to block the expression ... new study of mice that could lead to better ... Bolanos, an assistant professor of psychology and neuroscience, was ... of a gene called Brain Derived Neurotrophic Factor (BDNF) ...
... University of Minnesota Medical School and the Brain Sciences ... a new way to assess how brain networks act ... Institute (New Mexico) led Apostolos P. Georgopoulos, M.D., Ph.D., ... a novel way to assess the dynamic interactions of ...
... octopus arm is extremely flexible. Thanks to this ... infinite number of "degrees of freedom"--the octopus is ... that is unmatched by the human arm. Nonetheless, ... between the octopus and vertebrates, the octopus arm ...
Cached Biology News:It's in the genes: Study opens door to new treatment of the blues 2How the octopus forms an elbow 2